docetaxel anhydrous has been researched along with plerixafor in 8 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (plerixafor) | Trials (plerixafor) | Recent Studies (post-2010) (plerixafor) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 1,312 | 113 | 930 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | plerixafor (IC50) |
|---|---|---|---|
| C-X-C chemokine receptor type 4 | Rattus norvegicus (Norway rat) | 0.108 | |
| C-C chemokine receptor type 2 | Homo sapiens (human) | 0.0001 | |
| C-X-C chemokine receptor type 4 | Homo sapiens (human) | 0.3717 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, G; Ding, Y; Liu, B; Qian, X; Wei, J; Xie, L; Yu, L | 1 |
| Bouchez, LC; Cho, CY; Dubrovska, A; Elliott, J; Kularatne, SA; Reddy, VA; Salamone, RJ; Schepotin, IB; Schultz, PG; Stakhovsky, AE; Telegeev, GD; Trussell, C; Wang, Y; Watson, J; Yan, F | 1 |
| Ananias, HJ; de Jong, IJ; De Vries, EG; Domanska, UM; Huls, G; Kliphuis, NM; Kruizinga, RC; Nagengast, WB; Oude Munnink, TH; Timmer-Bosscha, H; Walenkamp, AM | 1 |
| Fujita, K; Hatano, K; Kaneda, Y; Murakami, K; Nagahara, A; Nakai, Y; Nakayama, M; Nimura, K; Nonomura, N; Tsuchiya, M; Uemura, M; Yamaguchi, S | 1 |
| Barwick, B; Boise, L; Chen, HR; Chen, J; Dong, JT; Fu, C; Kowalski, J; Kucuk, O; Li, M; Li, X; Li, Y; Osunkoya, AO; Qian, WP; Vertino, PM; Wu, D; Wu, Q; Xia, S; Xie, L; Yang, L; Zhang, B; Zhao, Y; Zhou, W | 1 |
| Arteaga, CL; Chu, F; Gagea, M; Hanash, S; Hanker, AB; Liu, S; Liu, W; Marchese, A; Neelapu, SS; Nguyen, N; Singareeka Raghavendra, A; Tripathy, D; Xie, SM; Yang-Kolodji, G; Zimmermann, J | 1 |
1 review(s) available for docetaxel anhydrous and plerixafor
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 other study(ies) available for docetaxel anhydrous and plerixafor
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer.
Topics: Benzylamines; Biomarkers; Cell Line, Tumor; Cyclams; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Heterocyclic Compounds; Humans; Receptors, CXCR4; Stomach Neoplasms; Taxoids | 2010 |
CXCR4 expression in prostate cancer progenitor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Adhesion; Cell Proliferation; Chemokine CXCL12; Cyclams; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Neoplasm Metastasis; Neoplastic Stem Cells; Prostatic Neoplasms; Receptors, CXCR4; Taxoids | 2012 |
CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chemokine CXCL12; Cyclams; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Prostatic Neoplasms; Random Allocation; Receptors, CXCR4; Taxoids; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc.
Topics: Animals; Antineoplastic Agents; Benzylamines; Carcinogenesis; Cell Line, Tumor; Cyclams; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Male; MAP Kinase Signaling System; Mice, Nude; Mice, SCID; Neoplasm, Residual; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Receptors, CXCR4; Signal Transduction; Taxoids | 2013 |
Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Neoplasms; Carcinogenesis; Cell Line, Tumor; Cyclams; Docetaxel; Epithelial-Mesenchymal Transition; Humans; Interleukin-11; Kruppel-Like Transcription Factors; Male; Mice; Mutation; Osteogenesis; Prostatic Neoplasms, Castration-Resistant; Receptors, CXCR4; Signal Transduction; Transforming Growth Factor beta | 2021 |
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Leukocytes, Mononuclear; Mice; Mitosis; Receptor, ErbB-2; Receptors, CXCR4; Trastuzumab; Tumor Microenvironment | 2023 |